Claim Amendment

In the claims

1. (Original) A method of treating rhinosinusitis or alleviating the symptoms of rhinosinusitis, comprising

administering an agent that permits the release of proteins from the endoplasmic reticulum.

2. (Original) The method of claim 1, wherein the agent is delivered intranasally.

3. (Original) The method of claim 1, further comprising the step of:

providing an individual suffering from rhinosinusitis.

4. (Original) The method of claim 3, wherein the providing step comprises providing an individual suffering from chronic rhinosinusitis.

5. (Original) The method of claim 3, wherein the individual carries a mutation in at least one copy of a gene encoding a cystic fibrosis transmembrane conductance regulator.

6. (Original) The method of claim 3, wherein the gene is the *CFTR* gene.

7. (Original) The method of claim 3, wherein the individual carries a mutation in one copy of the gene.

8. (Original) The method of claim 3, wherein the individual carries a mutation in both copies of the gene.

9. (Original) The method of claim 7 or claim 8, wherein the mutation is a ΔF508 mutation.

10. (Original) The method of claim 9, wherein the individual carries an M470V variant of the *CFTR* gene.

11 – 28. (Canceled)

29. (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent is a calcium pump inhibitor.

30. (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent decreases or inhibits the activity of UDP glucose:glycoprotein glycosyl transferase.

31. (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent decreases or inhibits activity of the endoplasmic reticulum Ca^{++} ATPase.

32. (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent lowers the concentration of Ca^{++} in the endoplasmic reticulum.

33. (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent causes release of Ca^{++} from the endoplasmic reticulum.

34. (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent stimulates or increases IP_3 receptor activity.

35. (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent decreases or inhibits calnexin functional activity

36. (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent increases or activates ryanodine receptor activity

37. (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent comprises thapsigargin or a derivative thereof.

20

~~38.~~ (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent comprises DBHQ or a derivative thereof.

21

~~39.~~ (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent comprises cyclopiazonic acid or a derivative thereof or wherein the agent comprises halothane or a derivative thereof.

22

~~40.~~ (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent permits release of mis-assembled or mis-folded proteins from the endoplasmic reticulum.

23

~~41.~~ (Currently amended) The method of ~~any of claims~~ claim 3, ~~12, 17, or 24,~~ wherein the agent is an oligonucleotide which is antisense to a protein selected from the group consisting of UDP glucose:glycoprotein glycosyl transferase, calnexin and Ca^{++} ATPase.

42 – 56. (Canceled)